BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 38124747)

  • 1. Mouse models of diffuse large B cell lymphoma.
    Tabatabai A; Arora A; Höfmann S; Jauch M; von Tresckow B; Hansen J; Flümann R; Jachimowicz RD; Klein S; Reinhardt HC; Knittel G
    Front Immunol; 2023; 14():1313371. PubMed ID: 38124747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
    Camicia R; Winkler HC; Hassa PO
    Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New murine models of aggressive lymphoma.
    Flümann R; Nieper P; Reinhardt HC; Knittel G
    Leuk Lymphoma; 2020 Apr; 61(4):788-798. PubMed ID: 31752573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.
    Knittel G; Liedgens P; Korovkina D; Pallasch CP; Reinhardt HC
    Eur J Haematol; 2016 Dec; 97(6):499-510. PubMed ID: 27526684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Doraiswamy A; Shah MR; Bannerji R
    Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
    Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Hoffmann MS; Hunter BD; Cobb PW; Varela JC; Munoz J
    Transplant Cell Ther; 2023 Jul; 29(7):440-448. PubMed ID: 37031747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathologically complete remission to combination of invariant NK T cells and anti-CD20 antibody in a refractory HIV+ diffuse large B-cell lymphoma patient.
    Wang J; Zhang R; Ding X; Jin Y; Qin R; Xia B; Liao Q; Hu H; Song W; Wang Z; Zhang X; Xu J
    Immunotherapy; 2022 Jun; 14(8):599-607. PubMed ID: 35443802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL.
    Jeyakumar N; Smith M
    Front Immunol; 2022; 13():887866. PubMed ID: 35663947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
    Mondello P; Steiner N; Willenbacher W; Ferrero S; Ghione P; Marabese A; Pitini V; Cuzzocrea S; Mian M
    Oncologist; 2016 Sep; 21(9):1107-12. PubMed ID: 27382029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4
    Falgàs A; Pallarès V; Unzueta U; Núñez Y; Sierra J; Gallardo A; Alba-Castellón L; Mangues MA; Álamo P; Villaverde A; Vázquez E; Mangues R; Casanova I
    Int J Nanomedicine; 2021; 16():1869-1888. PubMed ID: 33716502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma.
    Jin Z; Xiang R; Qing K; Li D; Liu Z; Li X; Zhu H; Zhang Y; Wang L; Xue K; Liu H; Xu Z; Wang Y; Li J
    Cell Oncol (Dordr); 2023 Aug; 46(4):1143-1157. PubMed ID: 37219767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.
    Chapuy B; Cheng H; Watahiki A; Ducar MD; Tan Y; Chen L; Roemer MG; Ouyang J; Christie AL; Zhang L; Gusenleitner D; Abo RP; Farinha P; von Bonin F; Thorner AR; Sun HH; Gascoyne RD; Pinkus GS; van Hummelen P; Wulf GG; Aster JC; Weinstock DM; Monti S; Rodig SJ; Wang Y; Shipp MA
    Blood; 2016 May; 127(18):2203-13. PubMed ID: 26773040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapsed/Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma.
    Maurer MJ; Jakobsen LH; Mwangi R; Schmitz N; Farooq U; Flowers CR; de Nully Brown P; Thompson CA; Frederiksen H; Cunningham D; Jørgensen J; Poeschel V; Nowakowski G; Seymour JF; Merli F; Haioun C; Ghesquieres H; Ziepert M; Tilly H; Salles G; Shi Q; El-Galaly TC; Habermann TM
    Am J Hematol; 2021 May; 96(5):599-605. PubMed ID: 33661547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma.
    Brooks TR; Caimi PF
    Blood Rev; 2024 Jan; 63():101140. PubMed ID: 37949705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial.
    Witzens-Harig M; Memmer ML; Dreyling M; Hess G
    BMC Cancer; 2013 Jun; 13():308. PubMed ID: 23799873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy and safety in relapsed/refractory diffuse large B-cell lymphoma: a systematic literature review.
    Colosia A; Njue A; Trask PC; Olivares R; Khan S; Abbe A; Police R; Wang J; Ruiz-Soto R; Kaye JA; Awan F
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):343-355.e6. PubMed ID: 24768510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and treatment patterns of relapsed/refractory diffuse large B-cell lymphoma in patients receiving ≥3 therapy lines in post-CAR-T era.
    Xie J; Wu A; Liao L; Nastoupil LJ; Du EX; Noman A; Chen L
    Curr Med Res Opin; 2021 Oct; 37(10):1789-1798. PubMed ID: 34344238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.
    Walji M; Assouline S
    Expert Rev Hematol; 2020 Sep; 13(9):933-942. PubMed ID: 32700586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Aggressive B Cell Lymphomas: Updates in 2019.
    Mondello P; Nowakowski GS
    Curr Hematol Malig Rep; 2020 Jun; 15(3):225-234. PubMed ID: 32372238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.